close
close

XyloCor Therapeutics and SmartWise enter into licensing agreement for use of Extroducer

XyloCor Therapeutics and SmartWise enter into licensing agreement for use of Extroducer
XyloCor Therapeutics and SmartWise enter into licensing agreement for use of Extroducer

XyloCor Therapeutics Inc., a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular diseases, and SmartWise, a unit of SmartCella Holding AB, have entered into a licensing agreement under which XyloCor obtains the rights to the Extroducer Infusion Catheter System, an endovascular device designed to deliver advanced therapies directly to the heart and hard-to-reach tissues.

XyloCor plans to use the Extroducer to support catheter-based endocardial delivery of its lead gene therapy candidate XC001 (encoberminogen rezmadenovec) in future clinical trials and commercial use.

“This agreement with SmartCella allows XyloCor to build on its strong foundation of efficacy and safety data for XC001 by providing the potential for improved safety and easier non-surgical administration via this novel catheter,” said Al Gianchetti, President and CEO of XyloCor. “The collaboration with SmartCella will help us optimize patient safety and tolerability while ensuring precise delivery of XC001 to target areas in the heart of patients with refractory angina. It also opens the potential to develop XC001 for even larger patient populations earlier in the course of coronary artery disease.”

XC001 is designed to reduce ischemic burden by creating new blood vessels in the heart through the local expression of multiple isoforms of vascular endothelial growth factor (VEGF). By using the Extroducer catheter, XyloCor can offer patients a better delivery option for local administration of XC001 directly to the heart that is less invasive and eliminates potential risks associated with surgical administration.

“The collaboration underscores the transformative potential of the Extroducer in delivering XC001 therapy to patients with refractory angina,” said Niklas Prager, CEO of SmartCella.

The terms of the agreement include a worldwide license to XyloCor to use the Extroducer to deliver XC001 and provide for SmartCella to supply catheters to XyloCor for clinical testing and commercial use. In exchange, the company will receive an upfront payment, clinical, regulatory and commercial milestones and a royalty on sales. The total value of the agreement is approximately $130 million and royalties in the mid-single digits.

Leave a Reply

Your email address will not be published. Required fields are marked *